For adults navigating the often-frustrating process of seeking an ADHD diagnosis and treatment, the standard of care is a fragmented journey. It can involve a months-long wait for a specialist, followed by a series of disjointed touchpoints for medication management, therapy, and coaching, each with its own cost and administrative burden. Agave Health is betting that a single, membership-based virtual home can replace that patchwork, offering diagnosis, therapy, coaching, and AI-powered tools under one roof [Agave Health website]. The New York-based startup, founded in 2022, is now building its case with a notable corporate partnership, aiming to prove its model can scale beyond direct-to-consumer channels.
A membership model for a fragmented condition
Agave's core proposition is a comprehensive ADHD care plan accessible via a monthly membership. The service bundles personalized coaching, behavioral therapy programs, and diagnostic assessments. Its AI-enhanced features, which include tools for reflection and insight generation, are positioned as supportive aids operating under human clinician oversight, not as replacements [Agave Health website]. This integrated approach targets a specific patient population: adults with ADHD, a group historically underserved by a healthcare system often focused on pediatric care. By consolidating services, Agave aims to address both the clinical and logistical pain points of managing a chronic neurodevelopmental condition.
The partnership as a proof point
The most concrete signal of traction for Agave Health comes not from public funding announcements, which remain undisclosed, but from a recent enterprise deal. In March 2026, the company announced a partnership with homebuilder Lennar and health platform Sharecare to provide ADHD care support to Lennar employees [Behavioral Health Business, 2026]. The program includes symptom measurement using the standardized ASRS-6 assessment, positioning Agave as a specialized vendor within a larger corporate wellness offering. This move validates the company's ability to interface with employer health plans and large partners, a critical channel for scaling digital health services. It also serves as a live pilot for measuring clinical outcomes and engagement in a defined population.
Building on founder experience and investor confidence
The team behind Agave brings a blend of operational and personal experience to the challenge. Co-founders Ori Fruhauf and Eve Lise Mamane are described as high-tech industry veterans [Agave Health about-us]. Fruhauf's background includes roles at digital health company DarioHealth Corp. and several entrepreneurial ventures [success.ai]. Mamane's motivation is cited as personal, stemming from her husband's experience with ADHD diagnosis and treatment [Graham & Walker]. They have secured backing from investors including Good Company, SeedIL Ventures, and Graham & Walker, though the specifics of their seed round are not public. Operational scale is suggested by third-party data estimating the company employs between 100 and 249 people [ZoomInfo].
Navigating a crowded and complex landscape
The bet Agave is making is substantial, but the path is lined with competitive and regulatory considerations. The virtual mental health and ADHD care space is increasingly crowded, with numerous telehealth providers offering similar services. Agave's differentiation rests on the depth of its integrated care model and its focus solely on ADHD, but it must continually demonstrate superior outcomes and member retention.
- Clinical oversight. The company emphasizes that its AI tools operate under clinician guidance. Maintaining this guardrail is non-negotiable for patient safety and regulatory compliance, especially as it scales.
- Reimbursement complexity. While the Lennar deal is a start, broader adoption hinges on navigating insurance reimbursement and proving value to employer benefits managers, a sales cycle known for its length and complexity.
- Outcome measurement. Success in digital health is increasingly defined by demonstrable improvements in patient-reported outcomes. Agave's use of the ASRS-6 in its partnership is a step in this direction, but building a robust outcomes database will be key for long-term credibility.
The standard of care for adult ADHD today is often a disconnected series of specialist visits, with therapy, coaching, and medication management handled by separate providers. This fragmentation leads to gaps in care, inconsistent follow-up, and high out-of-pocket costs. Agave Health's model proposes a coordinated alternative, but its ultimate test will be whether it can deliver measurably better health trajectories for its members at a sustainable cost. For the millions of adults managing ADHD, that outcome is the only metric that truly matters.
Sources
- [Agave Health website] Homepage and service description | https://www.agavehealth.com/
- [Agave Health about-us] About Us page | https://www.agavehealth.com/about-us
- [Behavioral Health Business, 2026] Proof Point: Inside the Lennar-Agave Health Partnership to Support Employees with ADHD | https://bhbusiness.com/2026/03/30/proof-point-inside-the-lennar-agave-health-partnership-to-support-employees-with-adhd/
- [Graham & Walker] G&W Portfolio Founder Feature: Eve Lise Mamane, Agave Health | https://grahamwalker.com/blog/gw-portfolio-founder-feature-eve-lise-mamane-agave-health/
- [success.ai] Ori Fruhauf profile | https://www.success.ai/profile/ori-fruhauf-97688598
- [ZoomInfo] Agave Health company data | https://www.zoominfo.com/c/agave-health-inc/378278945